| Market revenue in 2023 | USD 1,536.6 million |
| Market revenue in 2030 | USD 2,643.3 million |
| Growth rate | 8.1% (CAGR from 2024 to 2030) |
| Largest segment | Mammalian |
| Fastest growing segment | Mammalian |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Mammalian, Bacterial, Fungal |
| Key market players worldwide | Merck & Co Inc, DSM, CSPC Pharmaceutical Group Ltd, Teva Pharmaceutical Industries Ltd, Lonza Group Ltd, Takeda Pharmaceutical Co Ltd, Kolon Life Science, Shandong Lukang Pharmaceutical Group |
Publish Date: Apr 14, 2025
Last Updated: Aug 26, 2026
No credit card required*
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Teva Pharmaceutical Industries Ltd | View profile | 37,851 | 124 Dvora HaNevi’a Street, Tel Aviv, Israel, 6944020 | www.tevapharm.com |
| Lonza Group Ltd | View profile | 18,000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | www.lonza.com |
| Merck & Co Inc | View profile | 72,000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | www.merck.com |
| DSM | View profile | 10001+ | Heerlen, Limburg, The Netherlands, Europe | www.dsm.com |
| Takeda Pharmaceutical Co Ltd | View profile | 49,095 | 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan, 103-8668 | www.takeda.com |
| CSPC Pharmaceutical Group Ltd | View profile | 23,500 | No. 226 Huanghe Street, Hebei Province, Shijiazhuang, China, People's Republic of, 050035 | www.cspc.com.hk |
| Kolon Life Science | View profile | 251-500 | Seoul, Seoul-t'ukpyolsi, South Korea, Asia | www.kolonls.co.kr |
| Shandong Lukang Pharmaceutical Group | View profile | 5001-10000 | Jining, Shandong, China, Asia | www.lkpc.com |
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Microbial API Market Outlook will help companies and investors design strategic landscapes.
Mammalian was the largest segment with a revenue share of 47.41% in 2023.
Horizon Databook has segmented the Italy microbial api market based on mammalian, bacterial, fungal covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the Italy Microbial API Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Italy Microbial API Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.
